Valuation: Avalo Therapeutics, Inc.

Market Cap 965M 838M 780M 716M 1.35B 92.1B 1.38B 9.18B 3.61B 45.87B 3.63B 3.55B 152B P/E 2026 *
-7.39x
P/E 2027 * -6.1x
Enterprise Value 546M 474M 441M 405M 765M 52.09B 778M 5.19B 2.04B 25.94B 2.05B 2.01B 85.95B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.28%
Yield 2026 *
0.06%
Yield 2027 * -
1 day-5.88%
1 week-1.03%
1 month-1.24%
3 months+36.19%
6 months+20.78%
Current year+0.50%
1 week 18.24
Extreme 18.24
20.01
1 month 17.27
Extreme 17.27
20.65
Current year 12.51
Extreme 12.51
24.27
1 year 7.87
Extreme 7.87
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/7/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/6/26 Free

Director

1,080 0.0020%
30/6/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-5.88%-1.03%+131.31%-61.98% 965M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.70%-3.52%+44.16%+135.42% 23.48B
Weighted average by Cap. +0.21%-2.95%+29.09%+119.23%

Financials

2026 *2027 *
Net sales - -
Net income -85.72M -74.36M -69.21M -63.59M -120M -8.18B -122M -815M -320M -4.07B -322M -315M -13.49B -110M -95.78M -89.15M -81.91M -155M -10.53B -157M -1.05B -412M -5.25B -415M -406M -17.38B
Net Debt -419M -364M -339M -311M -588M -40.01B -597M -3.99B -1.57B -19.92B -1.57B -1.54B -66.01B -305M -265M -246M -226M -428M -29.11B -435M -2.9B -1.14B -14.5B -1.15B -1.12B -48.03B
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
31/07/26 USD 18.25 -5.88% 923,877
30/07/26 USD 19.39 +2.00% 935,221
29/07/26 USD 19.01 -2.61% 789,787
28/07/26 USD 19.52 +0.10% 815,719
27/07/26 USD 19.50 +5.75% 1,168,713
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.25USD
Average target price
44.69USD
Spread / Average Target
+144.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock